JPT and Immudex Announce Partnership Agreement

Copenhagen, Denmark and Berlin, Germany, November 5th, 2013.
Immudex and JPT Peptide Technologies today announced a partnership agreement on the co-distribution and co-promotion of their existing immunological product lines.
The goal of this partnership is to synergistically combine JPT’s innovative peptide-based core technologies and existing products with Immudex’s sophisticated Dextramer products for MHC multimer assays, in order to provide a comprehensive portfolio of high quality products and services for the immunotherapy and vaccine development community.

"This partnership is a win-win for the two companies," says Henrik Pedersen, CEO of Immudex and adds: "JPT is the leading provider of high performance peptide tools and services for monitoring both cellular and humoral immune responses. Likewise, Immudex has a constant focus on the quality and reliability of its MHC Dextramers and their application to the development of novel vaccines and immunotherapeutics. Teaming up with JPT will make it easier for our customers to access all those high quality products and services."

Holger Wenschuh, CEO of JPT states: "Immudex’s unique repertoire of high quality Dextramer multimers and related services for robust T-cell assays represents an ideal complement to our existing product portfolio supporting all phases of immunotherapy and vaccine development. Immudex’s commitment to quality and regulation of their production processes matches our vision to provide only products of highest value to researchers and clinicians in the vaccine and immunotherapy community. We have a high level of confidence that our worldwide customer base will recognize and appreciate our expanded product range in that arena."  

About Immudex
Based in Copenhagen, Denmark, with North American operations based in Fairfax, Virginia, Immudex provides MHC Dextramer reagents for the monitoring of antigen-specific T cells. Immudex also conducts the annual MHC Multimer and Elispot Proficiency Panels.  Immudex’s goal is to enable simple, accurate and reproducible monitoring of antigen-specific T cells in scientific and clinical research, patient care, and to promote the routine use of these technologies in diagnostics, research, as well as vaccine and immunotherapy development.
For further information please see  

About JPT Peptide Technologies GmbH
JPT Peptide Technologies GmbH, a wholly owned subsidiary of BioNTech AG (Mainz, Germany),  is a DIN ISO 9001:2008 certified research and development partner and innovative service provider for peptide related projects.  JPT’s key technologies SPOT - for ultra-high-throughput peptide synthesis and screening, PepStar™- for high-content peptide microarrays, PepTrack - for flexible peptide library assembly, PepMix - for antigen specific T-cell stimulation using peptide pools, and SpikeTide - for protein biomarker quantification accelerate research and development in areas such as immune monitoring, vaccine development, peptide biomarker discovery, peptide lead identification and optimization, enzyme profiling and proteomics. 
For further information please see    

For further information please contact:

JPT Peptide Technologies GmbH

Dr. Holger Wenschuh, CEO
Volmerstr. 5
12555 Berlin
Tel: +49 30 6392 5500
Fax: +49 30 6392 5501

Immudex ApS

Henrik Pedersen, CEO
Fruebjergvej 3
DK-2100 Copenhagen
Tel: +45 3917 9777

Stay in touch and be the first to receive the latest news!